Abstracts tagged "antinuclear antibodies (ANA) and systemic sclerosis"

Abstract Number: 2586 • 2013 ACR/ARHP Annual Meeting
Antinuclear Antibody Negative Systemic Sclerosis Patients Have Less Vasculopathic Disease Manifestations
Gloria Salazar¹, Shervin Assassi¹, Fredrick M. Wigley², Daniel Furst^3,4,5, Laura K. Hummers², Dinesh Khanna⁶, John Varga⁷, Elena Schiopu⁸, Virginia D. Steen⁹, Murray Baron¹⁰, Marie Hudson¹¹, Janet E. Pope^12,13, Monique E. Hinchcliff¹⁴, Marvin J. Fritzler¹⁵, David B. Robinson¹⁶, Robert W. Simms¹⁷, Richard M. Silver¹⁸, Tracy M. Frech¹⁹, Barri J. Fessler²⁰, Jerry A. Molitor²¹, Sara Zamanian²², Niall Jones²³, John D. Reveille¹, Frank C. Arnett¹ and Maureen D. Mayes²⁴, ¹Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³David Geffen School of Medicine, Div of Rheumatology, University of California at Los Angeles, Los Angeles, CA, ⁴Div of Rheumatology, UCLA Medical School, Los Angeles, CA, ⁵Rheumatology, UCLA, Los Angeles, CA, ⁶University of Michigan Health System, Ann Arbor, MI, ⁷Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁸Rheumatology/Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, ⁹Department of Rheumatology, Georgetown University Medical Center, Washington, DC, ¹⁰McGill University, Montreal, QC, Canada, ¹¹Rheumatology, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada, ¹²Univ of Western Ontario, London, ON, Canada, ¹³St Joseph Health Care, London, ON, Canada, ¹⁴Division of Rheumatology, Northwestern University Medical School, Chicago, IL, ¹⁵Medicine, University of Calgary, Calgary, AB, Canada, ¹⁶Arthritis Centre, University of Manitoba, Winnipeg, MB, Canada, ¹⁷Rheumatology, Boston University School of Medicine, Boston, MA, ¹⁸Div Rheumatology & Immunology, Medical University of South Carolina,Charleston,USA, Charleston, SC, ¹⁹Internal Medicine-Division of Rheumatology, University of Utah School of Medicine, SLC, UT, ²⁰Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ²¹Rheumatic/Autoimmune Diseases, Univ of MN MMC108, Minneapolis, MN, ²²Internal Medicine/Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ²³Rheumatology Clinic at 124th Street Medical Clinic, Edmonton, AB, Canada, ²⁴University of Texas Health Science Center at Houston, Houston, TX
Antinuclear Antibody Negative Systemic Sclerosis Patients Have Less Vasculopathic Disease ManifestationsBackground/Purpose: Systemic Sclerosis (SSc) is an autoimmune disease characterized by fibrosis of skin and internal…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].